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1. Introduction 
Suicide gene therapy for cancer treatment proposed by Moolten [1] started more than 25 
years ago and has gained momentum with little variations in the original technology. At the 
current statistics, worldwide 1550 clinical trials of gene therapy have been reported 
(http://www.wiley.co.uk/genmed/clinical) among them 7% using suicide gene therapy. 
HSV-TK is the most well characterized suicide gene used for cancer therapy and in other 
diseases without inducing significant systemic toxicity [2] [3]. Chemotherapeutic drugs used 
for cancer therapy are problematic because they do not discriminate in their mode of action. 
Currently available drugs in the market are not cancer specific so functional concentration 
level in tumors cannot be reached without off-target toxicity level. This is specifically true 
for solid tumors where vascularization is poor and necrotic at the center of the tumor due to 
low oxygen and nutrient supply [4][5]. However, when the drug is activated by locally 
enzymatic reactions in a timely fashion, the metabolite is toxic for the tissue. The most 
widely used suicide genes are Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK), and 
Cytosine Deaminase (CD) from the virus Herpes simplex or the bacterium Escherichia coli 
respectively [6][7]. 
Prior research has focused on the mechanism of initiation and development of tumors. It 
starts with the mutation of 1 or several genes, then gradually attains more genetic mutation 
and genomic instability during the evolution of tumor/cancer. Almost all the genes fall in 2 
categories – oncogenes (derived from proto-oncogene) and tumor suppressor genes. There 
are many ways to treat various tumors ranging from benign to metastatic. Among them 
surgery followed by chemotherapeutic drug treatments is the widely used method of choice 
that damages the DNA and renders the cells apoptotic. Additionally, tumors can be cured 
by more subtle ways by restoring the function of tumor suppressor genes or disabling 
oncogenes, to prime the immune cells to act and down-regulate angiogenesis and metastatic 
activities. Solid tumors can be treated by intra-tumor delivery of suicide genes. The protein 
product of these genes catalyzes the formation of highly toxic metabolites following the 
application of some lesser toxic prodrugs. This leads to apoptosis or programmed cell death 
of the treated cells [8]. The apoptotic cells invite immune cells that further clear the tumor 
zone by phagocytosis. 
Suicide gene therapy is also known as Gene Directed Enzyme/Prodrug therapy (GDEPT) or 
as Gene Prodrug Activation Therapy (GPAT). GDEPT can either take the form of CBT (cell 
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based therapy) where nearby cells of the tumor are modified to express suicide gene or the 
tumor itself expresses the suicide gene therapy. GDEPT can also be used for viral vectors 
which itself carries the suicide gene. GDEPT (Molecular chemotherapy) has advantages over 
classical therapy. As only tumor cells posses the enzyme that converts prodrug to active 
metabolites, it increases the toxicity level several fold inside the tumor whereas the vast 
majority of the host cells are unaffected. By using tumor specific regulatory elements 
(promoter) drugs can be activated only in tumor cells [9][10] has used the technique where 
the drug is only preferentially activated in the hypoxic regions of the tumor. By harnessing 
the bystander effects, more destruction of tumor cells have been rendered. 
2. Properties of suicide gene 
To be considered as a suicide gene, the product enzyme should be either absent or present 
in low concentrations (low expression) in the host. It should have a high catalytic activity, so 
that tumor cells can convert this prodrug even in low substrate concentration (high KCAT, 
low Km). To be considered as an ideal therapeutic agent, it should have/possess the 
following criteria. 1) The drug should be non-toxic or minimally toxic prior to activation and 
highly toxic after enzymatic activation. 2) The prodrug should be able to effectively 
penetrate the tumor, distributed and taken up by individual cells. 3) It should have a high 
affinity for the transduced suicide gene and low affinity for cellular enzyme. The HSV-TK 
enzyme has 1000 times more affinity for the substrate GCV than the host cell TK [11]. 4) The 
metabolite should have a half-life that extends long enough to kill the tumor so that drug is 
not lost before reaching its concentration.  
3. Types of suicide genes for therapy 
There are several suicide gene therapies. Among them HSV1-TK and cytodine deaminase 
are important. Cytidine Deaminase: Cytosine Deaminase (CD) is an enzyme found in some 
bacteria and fungi that deaminates cytosine to uracil [12]. It can also convert the nontoxic 5-
fluorocytosine (5-FC) into the toxic compound 5-fluorouracil (5-FU) [13]. Mammalian cells 
do not contain CD. This property allows the drug to be used for suicide gene therapy 
especially for the treatment of cancer. The sensitivity of tumor to CD drug depends on dose, 
duration etc. This review will mainly focus on HSV-TK gene therapy. 
HSV-TK: TK converts GCV into a toxic metabolite that kills cells widely used for cancer 
therapy. HSV1-TK can also phosphorylate various nucleoside analogs of GCV such as 
acyclovir, ganciclovir, and penciclovir. 
4. Mode of action of HSV-TK 
HSV-1 encodes about 70 genes some are immediate early genes. TK is one of the immediate 
early (IE) genes that give rise to a 376 amino acid long protein. IE genes can be defined as 
genes that show rapid and transient expression in the absence of de novo protein synthesis; 
some viruses posses IE genes. HSV1 virus is neurotropic (preferentially attacks nerve cells to 
avoid immune cells) and TK is necessary when the virus goes into the lytic cycle from a 
dormant stage in the neural cells. During TK suicide gene therapy, GCV is injected 
systemically way and upon reaching the tumor area, the drug is monophosphorylated by 
HSV-TK, and further phosphorylation is done by the host cell kinase. This triphosphate 
www.intechopen.com
 
Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK) 
 
67 
form of GCV (deoxythymidine triphosphate) is an analog of purine which inhibits DNA 
polymerase and is the most toxic. Cancer cells are actively proliferating and synthesizing 
DNA; the purine analogs GCV triphosphate competes with triphosphate substrate for DNA 
polymerase and are incorporated in the nascent DNA. This results the DNA polymerase 
enzyme stall and termination of nuclear and mitochondrial DNA synthesis initiating the 
cascades of apoptosis paths. [14][1]. The mechanism for cell death with HSV-TK is not 
completely known. Apoptosis induction or the sensitization of CD95- L, TNF, and TNF-
related apoptosis-inducing ligands may contribute to cell death [15]. Yang et al. suggested 
that apoptosis occurred as a result of GCV-induced cell cycle arrests rather than direct 
chemical effects [16]. Depletion of the T-cells had no effect on the response [17]. The 
bystander effect causes local inflammation and the apoptotic cells invites dendritic cells and 
immune effectors (immune response) and further clears the tumor [18][19]. 
5. Bystander effect mediated by gap junctions 
The bystander effect can amplify the effect of toxic drugs several fold. The toxic form of the 
drug should have diffusible property so that it can kill the non-transduced tumor cells 
through the bystander effect; in case of absence of diffusion, it should be taken up by 
surrounding cells by active transport. The action/effect of drug should also be cell cycle 
independent. Although cancer cells are highly proliferating, at a particular given time only a 
fraction of cells are dividing. In these cases drug distribution by diffusion is helpful. 
Moreover, in case of solid tumors only 10% of the cells can be transduced; in that case tumor 
ablation is mainly dependent on the bystander effect. Phospho-GCV is about a 500 daltons 
molecule. Such a small molecule should spread to surrounding cells by diffusion. But 
phospho-GCV is not dissolved in the cell lipid membrane. So, they spread to neighboring 
cells by gap junction that mainly consists of connexin family of proteins among them 
connexin-43 is the most studied. Gap junctions are a narrow connecting channel (2-3 nm 
diameter) between cells that facilitates the exchange of small molecules less than 1.5 kd in 
size. The gap is bridged by connexins, a family of 21 proteins. Gap junction exchanges small 
metabolites, second messengers and electric signals through a procedure called Gap 
Junctional Intercellular Communication (GJIC) [20]. Gap junction allows the ablation of the 
entire tumor although all cells in the tumor do not contain the suicide gene. This 
phenomenon is known as bystander effect and has boosted/amplified the toxic effect. Many 
kinds of cells express gap junction and are connected with neighboring cells. Some of the 
brain tumors (gliomas) do not express gap junctions or downregulate gap junctions [21]. 
Several studies have been done to deliver connexin-43 with the suicide gene so that the 
bystander effect through diffusion of active drug can take place. This was attempted by the 
pharmacological administration of cAMP analogs, hydroxyurea etc. [22]. Various reports of 
using connexin-26 and connexin-43 for the augmentation of the bystander effect have been 
published [23][9]. Solid tumors from both humans and rodents express lower amount of 
connexin and gap junction [24]. Established cell lines derived from tumors also 
downregulate expression of connexin and sometimes lack gap junction. Fusion proteins 
consisting of HSVtk and 11 amino acids from HIV-1 TAT protein have been demonstrated to 
provide gap-junction independent intercellular trafficking [25]. 
6. Variations of original HSV-TK approach 
HSV1-TK suicide gene therapy is used for glioma [26], prostate cancer [27], leukemia [28] 
and lymphoma. Potency of original HSV-TK has been improved by the application of 
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various strategies. An approach was made to deliver fusion protein of TK and viral 
tegument protein VP22 (to increase the bystander effect) [29] and by the use of fusion 
protein of HIV TAT and TK (that is more stable than wild type TK) [30]. Cerepro 
(sitimagene ceradenovec) is a recombinant adenoviral vector consisting of HSV-TK and 
replication deficient (where E1 and part of E3 genes have been deleted). After the brain 
surgery, this vector was injected immediately. Upon intra-peritoneal administration of GCV, 
the volume of the tumor was reduced [31]. It is found that GCV is a substrate for ABCG2 
(ATP-binding cassette sub-family G member 2, also known as the breast cancer resistance 
protein) and glioblastoma side population can pump out small molecule drugs like GCV 
rendering it resistant to therapy whereas non-side populations are susceptible [32]. Due to 
toxicity of the surrounding healthy tissue especially liver parenchyma cells in liver tumor, 
the use of TK has limited its clinical usefulness [33]. This problem has been improved by 
injecting the vector inside the tumor or using engineered HSV-TK under tumor specific 
promoter like α-fetoprotein. [34]. Ad.TK was injected intratumorally in hepatocellular 
carcinoma (HCC) and it did not show any toxicity in normal liver tissue and the therapy 
was well tolerated. Ad.TK can be safely used in HCC patient upto 2X1012 viral 
Particles/patient [35]. The HSV-TK gene has been successfully transferred into hepatoma 
cells (BEL-7402), and the growth potential of these cells was significantly inhibited by the 
application of GCV [36]. The bystander effect was further boosted by a combination therapy 
of co-expression of TK and E-cadherin genes in adenoviral vector. E-cadherin expression 
modulates the gap junction by connexin expression. It is assumed that E-cadherin 
expression facilitates connexin transport to the plasma membrane thus connexin stabilized 
and minimize connexin internalization and degradation by lysosomes and proteosome 
mediated degradation [37]. The role of E-cadherin in suicide gene therapy is established in 
an in vivo model of pancreatic ductal adenocarcinoma. This way it was possible to increase 
the bystander effect by treating the tumor with HSV-TK+E-cad [38]. Additionally, the 
increase of E-cad  expression. also down regulates bcl-2 (an anti-apoptotic gene) rendering 
cell death. Non-human primate marmoset is used as a transgenic model for preclinical 
studies. HSV-TK knock-in marmoset stem cell line (cmES) was established using RMCE (Cre 
recombinase-mediated cassette exchange). From the cmES cell line-generated tumor cells 
were effectively destroyed by GCV treatment. Thus, HSV-TK and GCV treatment may 
ensure safety of stem cell therapy [39]. In NSCLC (non-small cell lung cancer), human 
telomerase reverse transcriptase hTERT is up-regulated. Thus hTERT promoter controlled 
E1A (Ad.hTERT-E1A-TK /GCV) gene expression in NSCLC, efficiently killed different 
types of tumor cells and could be used a safe and potent therapy for NSCLC [40]. One group 
has used piggyBack vector for HSV-TK delivery and GCV treatment for gene therapy of 
cervical cancer [41]. Co-transfection of insulin like growth factor-I (IGF-I) and HSVTK by 
liposome promotes wound healing and minimizes the scar formation [42]. Adenoviral 
vectors containing HSVTK were transfected into T47D human breast cancer cells [43]. When 
grown in nude mice, administration of GCV markedly demonstrated regression of tumors 
over control animals [44]. Fong et al. demonstrated that ablation of CT26 tumor cells in situ 
was achieved by directly injecting high-titer HSV-TK retroviral vector preparations into the 
site of tumor cell inoculation followed by intra-peritoneal delivery of GCV [45]. 
Chondrosarcoma cells implanted into nude mice were injected with HSV-TK. After 4 weeks, 
the growth of tumors was significantly prevented [46]. Suicide gene therapy can be used as 
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a tool for molecular biology research. Evans G et al. have used HSV-TK suicide gene therapy 
to shut down Nerve Growth Factor (NGF) when its intended job is done i.e. the bridging of 
nerve gaps have been achieved [47]. Suicide gene was used as a molecular off switch for 
growth factor expression in a tissue engineered construct after the successful healing of the 
defect, both morphologically and functionally. NGF-producing HEK-293 called as hNGF-
EcR-293 cells were genetically modified to incorporate HSV-TK gene as a suicide gene for 
cell kill upon treatment with GCV. The combination of the inducible NGF expression system 
with the HSV-TK system offers regulation of time and presumed dose-dependent NGF 
expression at the site of the lesion with a subsequent elimination of genetically engineered 
cells within the conduit. 
 
 
Fig. 1. Conversion of Ganciclovir by HSV-TK and cellular kinase to Ganciclovir 
triphosphate. The drug GCV is monophosphorylated by HSV-TK, and further 
phosphorylation is done by the host cell kinase. This triphosphate form of GCV 
(deoxythymidine triphosphate) is an analog of purine which inhibits DNA polymerase and 
is the most toxic. The bystander effect is mediated by the intercellular gap junctions present 
in many kinds of tissues and tumors.  
One particular problem with the gene therapy is that retroviral vectors integrate in the 
genome randomly consequently it may potentially activate a proto-oncogene or silent a 
tumor suppressor gene rendering the cell to tumorigenesis. Insertion induced mutagenesis 
is a rare event at a frequency between 10-6 and 10-8 per insertion event [48]. Adenine 
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Deaminase (ADA) and Severe Combined Immuno-Deficiency (SCID) are genetic (inherited) 
disorders where the babies are born with immune deficiency and are vulnerable to common 
infections that others can resist in their everyday life. Several gene therapy approaches were 
used to deliver the corrected version of the gene in SCID patients by retroviral delivery. 
Patients regained immunity within 2-5 months but surprisingly several patients died due to 
cancer. Upon investigation, it was found that the virus has a preponderance to integrate in 
the vicinity of the human T-cell oncogene, LMO2 [49]. This probably due to retroviral 
transgene that has cotransforming role in leukemogenesis by giving advantages of increased 
cell proliferation or decreased apoptosis. As a cautionary measure, further trial of gene 
therapy was stopped. Delivery of HSV-TK fused with the therapeutic gene of interest into 
the therapeutic vector can be used for gene therapy. When the therapeutic gene has done its 
intended job, the cells harboring the gene and HSV-TK can be selectively eliminated by the 
administration of GCV. Thus killing the cells after gene therapy can be protective before the 
oncogene can do any harm. The GCV system has also been utilized in the non-oncologic 
setting. In vivo transduction with HSV-TK adenoviral vector followed by GCV treatment 
significantly inhibited the development of posterior capsule opacification from hyperplasia 
of the lens epithelium in the rabbit. Further, HSV-TK plasmid DNA has been injected into 
the joint space of rabbits with antigen-induced arthritis and when treated with GCV, results 
demonstrated a reduction in joint swelling in the HSV-TK–transduced knees [50]. Barbier et 
al. in an open and single-arm study on 48 patients, demonstrated that intracerebral injection 
of HSV-TK carrying cells into glioblastoma multiforme (GBM) did not result in any adverse 
effects [51]. HSV-TK has also been injected into the white matter of the right frontal lobe in 
two rhesus monkeys, with no clinical symptoms observed [52]. Murata et al. have 
demonstrated that like the Muristerone A–inducible system, the HSV-TK suicide gene 
allows for dose- and time-dependent regulation of cell death upon the application of  
GCV [53]. 
HSV-TK was modified to be able to migrate to neighboring cells and expand the expression 
of TK positive cells. A secreting form of HSV-TK was constructed by adding Igkappa leader 
peptide in the TK gene. An endoplasmic reticulum export signal was added to further 
increase the secretion. This resulted in the 70% of total protein secreted. However, enzyme 
activity of the secreted protein was decreased. This may present a hurdle for the 
development of a transmitted form of TK [54]. Microbubble destruction by ultrasound 
increases the efficiency of HSV-TK transfection [55]. HCC induces intrahepatic metastatic 
growth which is difficult to treat and prognosis is poor. A novel approach to introduce 
chemokine ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP-1) and HSV-TK 
together increases the efficiency of gene therapy. CCL2/MCP-1 attracts T helper 1-polarized 
antitumor activity without inducing tumor angiogenesis [56]. By using an IRES sequence, a 
plasmid was constructed with 2 suicide genes driven by PSMA promoter. The genes are 
FCY1 and HSV-TK for metabolizing the drug. Introducing the combination of 5-FC and 
GCV drugs inhibited the growth of prostate tumor compared to each drug individually. In a 
xenograft mouse model, retarded tumor growth was also observed. This suggests that the 
combination of multiple suicide genes may be more effective in prostate tumor [57]. 
Adenovirus mediated HSV-TK is a promising adjuvant therapy for patient’s having high 
grade glioma. This is a choice as surgery for malignant glioma is difficult due to its location 
and non-metastatic nature of glioma. The HSV-TK attacks the dividing tumor cells without 
harming healthy neurons which are non-dividing [58]. Pancreatic tumor was treated with 
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mesenchymal stem cells (MSC) containing a CCL5 promoter. Homing of MSC cells into 
primary pancreatic tumor stroma and activation of the CCL5 promoter takes place. About 
one week later after stem cell treatment tumor size reduced to 50% and metastasis reduced 
significantly [59]. Use of undifferentiated embryonic stem (ES) cells may form teratomas 
thus limiting the use of stem cells in clinical setting. However, HCV-TK with Oct4 promoter 
construct was injected to ES cells. Upon treatment with GCV, undifferentiated cells die but 
differentiated cells are free from harm [60]. Combination gene therapy using multidrug 
resistance (MDR1) shRNA and HPV-TK [61], targeting angiogenesis of hepatocellular 
carcinoma with GCV treatment has been done [62]. Transfection of wild type p53 makes C6 
glioma cells more susceptible to GCV treatment [63]. HIV-1 transactivator protein 
transduction domain (TAT PTD) can penetrate the cell. Cytotoxicity of GCV was enhanced 
by the fusion of HSV-TK and TAT PTD [64]. Fusion of mutant HSV-TK (with improved 
GCV activation) and guanylate kinase enhances prodrug sensitivity [65]. 
7. Disadvantage or drawback 
GCV has toxic side effects especially on bone marrow cells. So, it is administered in lower 
concentrations [66] and has been used in animal model studies. The disadvantage of using 
GCV is that although GCV is readily diffusible, its metabolite triphosphate is membrane 
insoluble and can’t diffuse to surrounding cells. However, the bystander effect of the close 
proximity/neighboring cells happen as triphosphate is transported to nearby cells through 
the gap junctions.  
8. Conclusion 
Suicide gene therapy is a method of choice to ablate cells in many diseases including cancer. 
But like other techniques this method is not fully safe and efficacious. HSV-TK gene therapy 
is still evolving and the method has been tinkered to be applicable in various cell 
background and different goal. More works need to be done for future applications. 
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